Equillium (EQ)
(Delayed Data from NSDQ)
$1.63 USD
-0.08 (-4.68%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $1.64 +0.01 (0.61%) 7:42 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Price, Consensus and EPS Surprise
EQ 1.63 -0.08(-4.68%)
Will EQ be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EQ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EQ
5 Stocks That More Than Doubled in Q1 With More Gains Ahead
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
EQ: What are Zacks experts saying now?
Zacks Private Portfolio Services
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark
Other News for EQ
Short interest on energy stocks up in March; APA and EQT most shorted, COP least shorted
EQ Inc. Celebrates a Profitable, Growth-Fueled Quarter
EQ Inc. Reports Profitable Fourth Quarter and 2023 Year End Financial Results
Buy Rating Affirmed for Equillium on Strong Clinical Data and Potential Financial Upsides
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)